241 related articles for article (PubMed ID: 18563174)
1. Immunotherapy for myeloid leukemias: current status and future directions.
el-Shami K; Smith BD
Leukemia; 2008 Sep; 22(9):1658-64. PubMed ID: 18563174
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches].
Mohty M; Gaugler B; Calmels B; Blaise D; Vey N; Chabannon C; Olive D
Bull Cancer; 2003; 90(8-9):751-7. PubMed ID: 14609765
[TBL] [Abstract][Full Text] [Related]
3. Vaccination for leukemia.
Molldrem JJ
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):13-8. PubMed ID: 16399579
[TBL] [Abstract][Full Text] [Related]
4. Cancer immune therapy for myeloid malignancies: present and future.
Holmström MO; Hasselbalch HC
Semin Immunopathol; 2019 Jan; 41(1):97-109. PubMed ID: 29987478
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic peptide vaccination with leukemia-associated antigens.
Rusakiewicz S; Molldrem JJ
Curr Opin Immunol; 2006 Oct; 18(5):599-604. PubMed ID: 16870418
[TBL] [Abstract][Full Text] [Related]
6. Current status of vaccination therapy for leukemias.
Reichardt VL; Brossart P
Curr Hematol Rep; 2005 Jan; 4(1):73-6. PubMed ID: 15610663
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil granule proteins as targets of leukemia-specific immune responses.
Barrett J; Rezvani K
Curr Opin Hematol; 2006 Jan; 13(1):15-20. PubMed ID: 16319682
[TBL] [Abstract][Full Text] [Related]
8. PR1 vaccination in myeloid malignancies.
Rezvani K
Expert Rev Vaccines; 2008 Sep; 7(7):867-75. PubMed ID: 18767937
[TBL] [Abstract][Full Text] [Related]
9. Peptide vaccine therapy for leukemia.
Rezvani K
Int J Hematol; 2011 Mar; 93(3):274-280. PubMed ID: 21380929
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of chronic myeloid leukemia: present state and future prospects.
Vonka V
Immunotherapy; 2010 Mar; 2(2):227-41. PubMed ID: 20635930
[TBL] [Abstract][Full Text] [Related]
11. Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines.
Ruben JM; Visser LL; Bontkes HJ; Westers TM; Ossenkoppele GJ; de Gruijl TD; van de Loosdrecht AA
Immunotherapy; 2013 Aug; 5(8):859-68. PubMed ID: 23902555
[TBL] [Abstract][Full Text] [Related]
12. Vaccines as consolidation therapy for myeloid leukemia.
Alatrash G; Molldrem JJ
Expert Rev Hematol; 2011 Feb; 4(1):37-50. PubMed ID: 21322777
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of acute myeloid leukemia: current approaches.
Smits EL; Berneman ZN; Van Tendeloo VF
Oncologist; 2009 Mar; 14(3):240-52. PubMed ID: 19289488
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?
Rafelson WM; Reagan JL; Fast LD; Lim SH
Leuk Lymphoma; 2017 Nov; 58(11):2523-2531. PubMed ID: 28351186
[TBL] [Abstract][Full Text] [Related]
15. Cancer vaccines for hematologic malignancies.
Borrello IM; Sotomayor EM
Cancer Control; 2002; 9(2):138-51. PubMed ID: 11965234
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation against leukemias and lymphomas: a realistic future treatment?
Mittal S; Marshall NA; Barker RN; Vickers MA
Crit Rev Oncol Hematol; 2008 Feb; 65(2):101-8. PubMed ID: 17719232
[TBL] [Abstract][Full Text] [Related]
17. Peptide vaccines for patients with acute myeloid leukemia.
Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
[TBL] [Abstract][Full Text] [Related]
18. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
H Yi D; Appel S
Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
[TBL] [Abstract][Full Text] [Related]
19. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy.
Goulmy E
Cancer J; 2004; 10(1):1-7. PubMed ID: 15000488
[TBL] [Abstract][Full Text] [Related]
20. Immunological weapons against acute myeloid leukaemia.
Galea-Lauri J
Immunology; 2002 Sep; 107(1):20-7. PubMed ID: 12225359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
